Eesti - eesti - Ravimiamet

meda pharma sia - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1annus 120annus 1tk; 50mcg+137mcg 1annus 120annus 3tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatiit, atoopiline - muud dermatoloogilised preparaadid - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.